World Smart Money
US Markets
Themes
πŸ’‰

GLP-1 & Obesity

GLP-1 leaders, next-gen candidates, CDMO, delivery devices, and disrupted incumbents

Approved Leaders
DuopolyLilly/Novo duopoly controls the incretin market; supply and oral formats decide share
Big Pharma EntrantsBig pharma buying into obesity via M&A pipelines, chasing a re-rated second tier
Next-Gen Pipeline
Clinical FrontrunnersNext-gen oral & triple-agonist leaders; pivotal readouts are the valuation catalyst
Novel MechanismsNovel mechanisms (amylin, muscle-sparing) bet on differentiated efficacy-safety profiles
Manufacturing & Tools
CDMO & Fill-FinishCDMO and sterile fill-finish are the capacity bottleneck β€” high-visibility GLP-1 beneficiaries
Delivery DevicesAutoinjector pens & delivery devices ride GLP-1 volume β€” pure unit-growth exposure
Diagnostics & MonitoringCGM and monitoring devices piggyback on metabolic-health adoption β€” positive narrative
Bariatric & Surgery
Impacted DevicesGLP-1s cannibalize bariatric surgery β€” structural headwind for affected device makers
Channel & Distribution
Pharmacy & PBMPharmacy/PBM and telehealth own the dispensing gateway β€” volume vs. margin tug-of-war
Drug WholesaleDrug-wholesale oligopoly earns fee-per-script β€” steady beneficiary of high-priced GLP-1s
Disrupted Incumbents
Food & BeverageFood & beverage giants face appetite-suppression demand risk β€” long-term volume pressure

Theme lists curated by Claude and may have gaps; quotes live. Research only, not investment advice. Β· Updated 2026-06-28